0
Article ? AI-assigned paper type based on the abstract. Classification may not be perfect — flag errors using the feedback button. Tier 2 ? Original research — experimental, observational, or case-control study. Direct primary evidence. Environmental Sources Human Health Effects Sign in to save

Opportunities and Challenges for Nanotherapeutics for the Aging Population

Frontiers in Nanotechnology 2022 28 citations ? Citation count from OpenAlex, updated daily. May differ slightly from the publisher's own count. Score: 50 ? 0–100 AI score estimating relevance to the microplastics field. Papers below 30 are filtered from public browse.
Nicholas J. Hunt, Peter McCourt, Zdenka Kuncic, David G. Le Couteur, Victoria C. Cogger

Summary

This review explores how nanotherapeutics could address age-related changes in drug pharmacokinetics that impair efficacy and increase toxicity in elderly patients, while noting the need to balance benefits against the long-term safety of nanomaterials.

Body Systems

Nanotherapeutics utilize the properties of nanomaterials to alter the pharmacology of the drugs and therapies being transported, leading to changes in their biological disposition (absorption, distribution, cellular uptake, metabolism and elimination) and ultimately, their pharmacological effect. This provides an opportunity to optimize the pharmacology of drugs, particularly for those that are dependent on hepatic action. Old age is associated with changes in many pharmacokinetic processes which tend to impair drug efficacy and increase risk of toxicity. While these age-related changes are drug-specific they could be directly addressed using nanotechnology and precision targeting. The benefits of nanotherapeutics needs to be balanced against toxicity, with future use in humans dependent upon the gathering of information about the clearance and long-term safety of nanomaterials.

Sign in to start a discussion.

Share this paper